<DOC>
	<DOCNO>NCT02194829</DOCNO>
	<brief_summary>This partially randomized phase I/II trial study side effect best dose WEE1 inhibitor MK-1775 give together paclitaxel albumin-stabilized nanoparticle formulation gemcitabine hydrochloride well work treat patient previously untreated pancreatic cancer spread another place body remove surgery . Drugs use chemotherapy , paclitaxel albumin-stabilized nanoparticle formulation gemcitabine hydrochloride , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . WEE1 inhibitor MK-1775 may stop growth tumor cell block enzymes need cell growth . It yet know whether paclitaxel albumin-stabilized nanoparticle formulation gemcitabine hydrochloride effective without WEE1 inhibitor MK-1775 treating patient pancreatic cancer .</brief_summary>
	<brief_title>Paclitaxel Albumin-Stabilized Nanoparticle Formulation Gemcitabine Hydrochloride With Without WEE1 Inhibitor MK-1775 Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic Can Be Removed Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate toxicity combination therapy nab-paclitaxel ( paclitaxel albumin-stabilized nanoparticle formulation ) , gemcitabine ( gemcitabine hydrochloride ) AZD1775 ( WEE1 inhibitor MK-1775 ) patient treatment-naive metastatic adenocarcinoma pancreas locally-advanced adenocarcinoma pancreas surgically resectable . ( Phase I ) II . To determine dose AZD1775 use combination nab-paclitaxel gemcitabine chemotherapy phase II portion trial . ( Phase I ) III . To determine pharmacokinetics AZD1775 combination nab-paclitaxel gemcitabine . ( Phase I ) IV . To evaluate progression-free survival ( PFS ) associate nab-paclitaxel/gemcitabine/placebo nab-paclitaxel/gemcitabine/AZD1775 patient metastatic adenocarcinoma pancreas . ( Phase II ) SECONDARY OBJECTIVES : I . To evaluate overall survival ( OS ) associate nab-paclitaxel/gemcitabine/placebo nab-paclitaxel/gemcitabine/AZD1775 patient metastatic adenocarcinoma pancreas . ( Phase II ) II . To evaluate response rate ( complete response [ CR ] + partial response [ PR ] ) associate nab-paclitaxel/gemcitabine/placebo nab-paclitaxel/gemcitabine/AZD1775 patient metastatic adenocarcinoma pancreas . ( Phase II ) III . To evaluate disease control rate ( CR + PR + stable disease [ SD ] ) associate nab-paclitaxel/gemcitabine/placebo nab-paclitaxel/gemcitabine/AZD1775 patient metastatic adenocarcinoma pancreas . ( Phase II ) TERTIARY OBJECTIVES : I . To evaluate ability AZD1775 inhibit Wee1 increase deoxyribonucleic acid ( DNA ) damage tumor cell death combine nab-paclitaxel/gemcitabine compare nab-paclitaxel/gemcitabine/placebo . ( Phase II ) II . To evaluate biomarker change tumor tissue associate Wee1 inhibition may also present hair follicle . ( Phase II ) III . To evaluate change tumor fludeoxyglucose ( FDG ) uptake ( maximum standardize uptake value [ SUVmax ] ) baseline FDG-positron emission tomography ( PET ) week 4 FDG-PET predictor response use Response Evaluation Criteria Solid Tumors ( RECIST ) reference standard response . ( Phase II ) IV . To evaluate change tumor FDG uptake ( SUVmax ) baseline FDG-PET week 4 FDG-PET predictor progression-free survival . ( Phase II ) V. To compare change tumor FDG uptake ( SUVmax ) baseline FDG-PET week 4 FDG-PET patient treatment arm C D. ( Phase II ) VI . To evaluate early increase tumor fluorothymidine ( FLT ) uptake ( FLT-flare ) observe within 24 hour initiation treatment nab-paclitaxel/gemcitabine/placebo . ( Phase II ) VII . To evaluate early ( within 24 hour [ h ] ) increase tumor FLT uptake ( FLT-flare ) abrogate initiation treatment nab-paclitaxel/gemcitabine/AZD1775 . ( Phase II ) VIII . To compare change tumor FLT uptake ( SUVmax ) baseline 24 hour initiation treatment patient treatment arm C D. ( Phase II ) OUTLINE : This phase I , dose escalation study WEE1 inhibitor MK-1775 follow randomized phase II study . Patients phase I assign arm A B patient phase II randomize arm C D. ARM A ( PHASE I , DOSE LEVEL 1 ) : Patients receive paclitaxel albumin-stabilized nanoparticle formulation intravenously ( IV ) 30 minute gemcitabine hydrochloride IV 30 minute day 1 , 8 , 15 . Patients also receive WEE1 inhibitor MK-1775 orally ( PO ) daily day 1 , 2 , 8 , 9 , 15 , 16 . ARM B ( PHASE I , DOSE LEVEL 2 ) : Patients receive paclitaxel albumin-stabilized nanoparticle formulation , gemcitabine hydrochloride , WEE1 inhibitor MK-1775 Arm A . ARM C ( PHASE II , PLACEBO ) : Patients receive paclitaxel albumin-stabilized nanoparticle formulation gemcitabine hydrochloride Arm A . Patients also receive placebo PO daily day 1 , 2 , 8 , 9 , 15 , 16 . ARM D ( PHASE II , WEE1 INHIBITOR MK-1775 ) : Patients receive paclitaxel albumin-stabilized nanoparticle formulation , gemcitabine hydrochloride , WEE1 inhibitor MK-1775 Arm A . In arm , course repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>PHASE I STUDY ARM A ( DOSE LEVEL 1 ) AND ARM B ( DOSE LEVEL 2 ) Patients must histologically cytologically confirm metastatic unresectable locally advanced adenocarcinoma pancreas prior systemic therapy metastatic locally advanced disease Previous neoadjuvant adjuvant treatment allow provide give &gt; = 6 month prior registration Patients must NOT receive investigational agent concurrently must receive investigational agent = &lt; 4 week prior registration Patients must preexist &gt; grade 1 motor sensory neuropathy Patients must NOT history allergic reaction attribute compound similar chemical biologic composition nabpaclitaxel , gemcitabine AZD1775 Patients must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patients must life expectancy &gt; = 12 week Patients may prior radiotherapy metastatic disease long &gt; 4 week prior registration patient recover adverse event associate radiotherapy Patients must NOT take current medication substance inhibitor inducer cytochrome P450 family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) Patients must NOT uncontrolled serious medical illness include , limited , ongoing active infection , cardiac arrhythmia , psychiatric illness would limit compliance study requirement Patients know human immunodeficiency virus ( HIV ) eligible cluster differentiation ( CD ) 4 count = &lt; 200 cell/mm^3 receive antiretroviral therapy Patients must able swallow capsule whole Patients must NOT previous concurrent malignancy ; exception make patient meet following condition : Nonmelanoma skin cancer , situ cervical cancer , breast cancer situ , superficial bladder cancer ( noninvasive papillary carcinoma carcinoma situ ) Prior malignancy completely excise remove patient continuously disease free &gt; 5 year Patients must able tolerate compute tomography ( CT ) , magnetic resonance imaging ( MRI ) PET image include contrast agent Women must pregnant breastfeeding Females childbearing potential must blood test urine study within 5 day prior registration rule pregnancy ; female childbearing potential woman , regardless sexual orientation whether undergone tubal ligation , meet follow criterion : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; two barrier method birth control ; abstinence ) duration study treatment 3 month last dose study treatment ; woman become pregnant suspect pregnant participating study , inform treat physician immediately ; man impregnate suspect impregnate woman participate study , inform treat physician immediately Leukocytes &gt; = 3,000/mcL Absolute neutrophil count &gt; = 1,500/mcL Hemoglobin &gt; = 9 g/dL Platelets &gt; = 100,000/mcL Total bilirubin = &lt; 1.5 institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 3 X institutional upper limit normal ( ULN ) = &lt; 5 X ULN patient liver metastasis Creatinine = &lt; 1.5 mg/dL creatinine clearance ( CockcroftGault ) &gt; = 60 mL/min patient creatinine level institutional upper limit normal ( ULN ) RANDOMIZED PHASE II STUDY ARMS C AND D PHASE II : Patients must histologically cytologically confirm metastatic adenocarcinoma pancreas prior systemic therapy metastatic disease PHASE II : Patients must NOT locally advance disease PHASE II : Patients must measurable disease outside primary tumor ( pancreas ) RECIST 1.1 criterion ; baseline measurement evaluation site disease must obtain = &lt; 4 week prior randomization PHASE II : Previous neoadjuvant adjuvant treatment allow provided evidence recurrent disease least 6 month completion neoadjuvant/adjuvant treatment PHASE II : Patients may prior radiotherapy metastatic disease long &gt; 4 week prior randomization patient recover adverse event associate radiotherapy PHASE II : Patients must NOT take current medication substance inhibitor inducer CYP3A4 PHASE II : Patients must NOT receive prior Wee1 inhibitor AZD1775 PHASE II : Patients must NOT receive gemcitabine nabpaclitaxel metastatic setting PHASE II : Patients must NOT receive investigational agent concurrently must receive investigational agent = &lt; 4 week prior randomization PHASE II : Patients must preexist &gt; grade 1 motor sensory neuropathy PHASE II : Patients must NOT history allergic reaction attribute compound similar chemical biologic composition nabpaclitaxel , gemcitabine AZD1775 PHASE II : Patients must ECOG performance status 0 1 PHASE II : Patients must life expectancy &gt; = 12 week PHASE II : Patients must NOT uncontrolled serious medical illness include , limited , ongoing active infection , cardiac arrhythmia , psychiatric illness would limit compliance study requirement PHASE II : Patients must able swallow capsule whole PHASE II : Patients biliary stent allow PHASE II : Patients must NOT previous concurrent malignancy ; exception make patient meet following condition : Nonmelanoma skin cancer , situ cervical cancer , breast cancer situ , superficial bladder cancer ( noninvasive papillary carcinoma carcinoma situ ) â€¢ Prior malignancy completely excise remove patient continuously disease free &gt; 5 year PHASE II : Patients must able tolerate CT , MRI PET image include contrast agent PHASE II : Women must pregnant breastfeeding Females childbearing potential must blood test urine study within 5 day prior randomization rule pregnancy ; female childbearing potential woman , regardless sexual orientation whether undergone tubal ligation , meet follow criterion : 1 ) undergone hysterectomy bilateral oophorectomy ; 2 ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) PHASE II : Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; two barrier method birth control ; abstinence ) duration study treatment 3 month last dose study treatment ; woman become pregnant suspect pregnant participating study , inform treat physician immediately ; man impregnate suspect impregnate woman participate study , inform treat physician immediately PHASE II : Leukocytes &gt; = 3,000/mcL PHASE II : Absolute neutrophil count &gt; = 1,500/mcL PHASE II : Hemoglobin &gt; = 9 g/dL PHASE II : Platelets &gt; = 100,000/mcL PHASE II : Total bilirubin = &lt; 1.5 institutional upper limit normal ( ULN ) PHASE II : AST ( SGOT ) /ALT ( SGPT ) = &lt; 3 X institutional upper limit normal ( ULN ) = &lt; 5 X ULN patient liver metastasis PHASE II : Creatinine = &lt; 1.5 mg/dL creatinine clearance ( CockcroftGault ) &gt; = 60 mL/min patient creatinine level institutional upper limit normal ( ULN ) PHASE II : For participation image research study , patient must meet additional follow criterion : PHASE II : The patient participate trial institutional agree perform image research study , complete American College Radiation Imaging Network ( ACRIN ) define scanner qualification procedure receive ACRIN approval PHASE II : The patient consent write participate one image research study PHASE II : The patient meet criteria require imaging study site participating : NOTE : Eligibility participate either image substudy depend availability image substudy particular institution For participation FDGPET substudy : Patients must NOT poorly control diabetes ( define fast glucose level &gt; = 200 mg/dL ) despite effort improve glucose control fast duration adjustment medication Patient must NOT weigh maximum weight limit PET table Patients must evaluable lesion &gt; 20 mm size standard practice image study assess site ( either primary pancreas mass metastasis ) For participation FLTPET substudy : Patients must able lie still 1.5 hour PET scan . Patient must NOT history allergic reaction attributable compound similar chemical biologic composition 18Ffluorothymidine Patient must NOT weigh maximum weight limit PET table Patients must evaluable lesion pancreas &gt; 20 mm size standard practice image study assess site ( lesion must likely primary adenocarcinoma pancreas primarily fibrotic mucinous nature )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>